UNICA IRIS Institutional Research Information System

PUZZONI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 60.023
NA - Nord America 3.163
AS - Asia 1.941
SA - Sud America 299
AF - Africa 53
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 65.483
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 59.195
US - Stati Uniti d'America 3.086
SG - Singapore 857
CN - Cina 521
BR - Brasile 223
VN - Vietnam 222
SE - Svezia 203
DE - Germania 123
FR - Francia 99
FI - Finlandia 81
GB - Regno Unito 80
HK - Hong Kong 70
IN - India 67
UA - Ucraina 66
NL - Olanda 46
CA - Canada 45
KR - Corea 24
MX - Messico 23
AR - Argentina 21
BD - Bangladesh 21
JP - Giappone 21
PL - Polonia 21
AT - Austria 20
IQ - Iraq 20
ES - Italia 18
TR - Turchia 18
ZA - Sudafrica 17
EC - Ecuador 16
CO - Colombia 14
ID - Indonesia 14
PK - Pakistan 14
IE - Irlanda 13
VE - Venezuela 12
MA - Marocco 11
RU - Federazione Russa 11
BE - Belgio 9
PH - Filippine 8
AE - Emirati Arabi Uniti 7
IR - Iran 7
KG - Kirghizistan 7
UZ - Uzbekistan 7
SA - Arabia Saudita 6
TN - Tunisia 6
IL - Israele 5
TH - Thailandia 5
CL - Cile 4
CZ - Repubblica Ceca 4
EG - Egitto 4
KE - Kenya 4
MK - Macedonia 4
PE - Perù 4
AU - Australia 3
GR - Grecia 3
LT - Lituania 3
LV - Lettonia 3
NP - Nepal 3
PY - Paraguay 3
RS - Serbia 3
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
DZ - Algeria 2
HU - Ungheria 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
SV - El Salvador 2
BB - Barbados 1
BH - Bahrain 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MN - Mongolia 1
MT - Malta 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 65.482
Salva come PNG Salva come JPEG
Città #
Cagliari 57.323
Uta 1.551
Singapore 506
Ashburn 386
Dallas 290
Fairfield 245
San Jose 230
Boardman 144
Woodbridge 133
Nyköping 129
Houston 126
Seattle 112
Beijing 111
Chandler 111
Los Angeles 89
Cambridge 87
Wilmington 77
Dearborn 69
Ho Chi Minh City 66
New York 63
Hong Kong 62
Santa Clara 58
Helsinki 56
The Dalles 53
Ann Arbor 51
Hanoi 42
Rome 40
Shanghai 39
Lauterbourg 38
Boston 37
Jacksonville 30
Dong Ket 28
Orem 28
Amsterdam 26
Buffalo 26
Frankfurt am Main 25
Hefei 25
Munich 25
São Paulo 25
Chicago 24
Nanjing 23
Seoul 23
London 21
Council Bluffs 20
Redondo Beach 19
Guangzhou 18
Nuremberg 18
San Diego 17
Warsaw 17
Toronto 16
Milan 15
Paris 15
Pune 14
Shenyang 13
Tokyo 13
Düsseldorf 12
Hangzhou 12
Turku 12
Atlanta 11
Chennai 11
Montreal 11
Poplar 11
Zhengzhou 11
Brooklyn 9
Dublin 9
Phoenix 9
Stockholm 9
Tianjin 9
Vienna 9
Changsha 8
Da Nang 8
Haiphong 8
Mont-saint-hilaire 8
Naples 8
Rio de Janeiro 8
Shenzhen 8
Wuhan 8
Augusta 7
Baghdad 7
Bishkek 7
Casablanca 7
Jiaxing 7
Johannesburg 7
Mumbai 7
Tashkent 7
Belo Horizonte 6
Biên Hòa 6
Buenos Aires 6
Hải Dương 6
Medellín 6
Nanchang 6
New Delhi 6
Quito 6
Redwood City 6
Salt Lake City 6
Selargius 6
Bexley 5
Boulder 5
Brussels 5
Centro 5
Totale 63.199
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.176
Clustered protocadherins methylation alterations in cancer 3.318
BRAF-mutant colorectal cancer, a different breed evolving 3.244
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.980
Molecular-biology-driven treatment for metastatic colorectal cancer 2.771
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.687
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.636
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.450
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.365
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.333
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.141
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 2.124
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.977
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.690
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.635
Immunotherapy and Cancer: The Multi-Omics Perspective 1.609
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.541
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.417
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.359
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.344
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.296
Immunotherapy for colorectal cancer: where are we heading? 1.273
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.268
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.222
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 1.096
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.076
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 1.013
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 988
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 963
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 960
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 786
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 776
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? 741
Uncovering key targets of success for immunotherapy in pancreatic cancer 722
Cholangiocarcinoma: new perspectives for new horizons 717
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 598
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study 507
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon 435
Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-RAS and N-RAS wild type metastatic colorectal cancer (SUPER-PEAK) 349
CD44: A New Prognostic Marker in Colorectal Cancer? 272
A new prognostic score for biliary tract cancer: a multicenter experience 218
REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol) 217
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 210
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 200
Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment 200
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience 184
Medical management of malignant bowel obstruction: our center experience 173
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions 170
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 170
LONG-TERM RESPONSE TO SUNITINIB, EVEROLIMUS AND AXITINIB SEQUENTIALLY USED IN A YOUNG WOMEN WITH MRCC. A CASE REPORT 146
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer 117
Preoperatory FLOT Regimen for Gastroesophageal Cancer and Renal Function: A New Onco-Nephrological Perspective 116
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 106
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study 103
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 102
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 100
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 100
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 96
The correlation between L1CAM expression and outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy 93
Totale 65.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.223 0 0 0 0 0 0 0 0 0 923 794 506
2021/20223.263 341 193 156 245 212 210 192 221 297 365 335 496
2022/20235.508 509 934 730 402 390 440 230 413 343 500 378 239
2023/20247.333 338 205 187 345 509 854 854 2.301 271 372 562 535
2024/202514.465 4.177 4.456 1.416 1.341 691 965 752 66 159 132 110 200
2025/20264.559 382 281 470 432 376 357 1.055 447 310 449 0 0
Totale 65.676